Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links

BBA Clinical

Volumn 5, Issue , 2016, Pages 16-24

  Jurjus, Abdo ^a,b   Eid, Assad ^a   Al Kattar, Sahar ^a   Zeenny, Marie Noel ^a   Gerges Geagea, Alice ^b   Haydar, Hanine ^a   Hilal, Anis ^a   Oueidat, Doreid ^a   Matar, Michel ^b   Tawilah, Jihane ^b   Hussein, Inaya Hajj ^c   Schembri Wismayer, Pierre ^d   Cappello, Francesco ^e   Tomasello, Giovanni ^e   Leone, Angelo ^e   Jurjus, Rosalyn A ^f  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Lebanese Health Society   (Lebanon)

^c OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MALTA   (Malta)

^e UNIVERSITY OF PALERMO   (Italy)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

CRC; Dysbiosis; IBD; Inflammation; Probiotic; T2DM

Indexed keywords

BIFIDOBACTERIUM; CARCINOGENESIS; COLORECTAL CANCER; CROHN DISEASE; EPITHELIAL MESENCHYMAL TRANSITION; GLUCOTOXICITY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MICROFLORA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 84949035700     PISSN: 22146474     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbacli.2015.11.002     Document Type: Review

References (65)

1. Ahmed M.Z.D., Xu R. Nuclear factor-kappaB in inflammatory bowel disease and colorectal cancer. S -. Am. J. Dig. Dis. 2014.
2. Ostadrahimi A., Taghizadeh A., Mobasseri M., Farrin N., Payahoo L., Gheshlaghi Z.B., Vahedjabbari M. Effect of probiotic fermented milk (Kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Iranian J. Public Health 2015.
3. Bellavia M., Rappa F., Lo Bello M., et al. Lactobacillus casei and Bifidobacterium lactis supplementation reduces tissue damage of intestinal mucosa and liver after 2,4,6-trinitrobenzenesulfonic acid treatment in mice. J. Biol. Regul. Homeost. Agents 2014, 28(2):251-261.
4. Dai C., Zheng C.Q., Meng F., Zhou Z., Sang L., Jiang M. VSL#3 Probiotics Exerts the Anti-Inflammatory Activity via PI3k/Akt and NF-κB Pathway in rat Model of DSS-Induced Colitis-Molecular and Cellular Biochemistry 2013, Springer.
5. Min C., Eddy S.F., Sherr D.H., Sonenshein G.E. NF-κB and Epithelial to Mesenchymal Transition of Cancer. Journal of Cellular Biochemistry 2008, Wiley Online Library.
6. Collins D., Hogan A.M., Winter D.C. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 2011, 12(5):504-512.
7. Couturier-Maillard A., Secher T., Rehman A., et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 2013, 123(2):700-711.
8. Cannata D., Fierz Y., Vijayakumar A., LeRoith D. Type 2 Diabetes and Cancer: What is the Connection? Mount Sinai Journal of Medicine 2010, Wiley Online Library.
9. DM Lilly, RH Stillwell. Probiotics: growth-promoting factors produced by microorganisms-Science, 1965.
10. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes Atlas: Global Estimates of the Prevalence of Diabetes for 2011 and 2030-Diabetes Research and Clinical Practice 2011, Elsevier.
11. Balkwill F. Tumour necrosis factor and cancer. Nat. Rev. Cancer, nature 2009.
12. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.W., Kagnoff M.F., Egan L.J., et al. IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer. Cell 2004, Elsevier.
13. Ganepola G.A.P., Nizin J., Rutledge J.R., Chang D.H. Use of blood-based biomarkers for early diagnosis and surveillance of colorectal cancer. J. Gastrointestinal Enterology 2014.
14. Hundorfean G., Neurath M.F., Mudter J. Functional Relevance of T Helper 17 (Th17) Cells and the IL-17 Cytokine Family in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2012, Wiley Online Library.
15. Griffin G.K., Newton G., Tarrio M.L., Bu D., Alcaide P., Azcutia V., Garcia E.M., et al. IL-17 and TNF-α sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. J. Immunol. 2012.
16. Monteleone G., Pallone F., Stolfi C. The dual role of inflammation in colon carcinogenesis. Int. J. Mol. Sci. 2012.
17. Tomasello G., Tralongo P., Damiani P., Sinagra E., Trapani B., Zeenny M.N., Hussein I.H., Jurjus A., Leone A. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes. World J. Gastroenterol. 2014.
18. Yadav H., Quijano C., Kamaraju A.K., Gavrilova O., Malek R., Chen W., Zerfas P. Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling, Cell Metabolism 2011, Elsevier.
19. Hajj Hussein I.A., Tohme R., Barada K., Mostafa M.H., Freund J.N., Jurjus R.A., Karam W., Jurjus A. Inflammatory bowel disease in rats: bacterial and chemical interaction. World J. Gastroenterol. 2008.
20. Andújar I., Recio M.C., Giner R.M., Jovellanos E., Laghi S., Muguerza B., Ríos J.L. Inhibition of ulcerative colitis in mice after oral administration of a polyphenol-enriched cocoa extract is mediated by the inhibition of STAT1 and STAT3 phosphorylation in colon cells. J. Agric. Food Chem. 2011.
21. Cheng I., Caberto C.P., Jones A.L., Seifried A., Wilkens L.R., Schumacher F.R., Monroe K.R. Type 2 diabetes risk variants and colorectal cancer risk: the multiethnic cohort and PAGE studies. Gut 2011.
22. Crncec I., Pathria P., Svinka J., Eferl R. Induction of Colorectal Cancer in Mice and Histomorphometric Evaluation of Tumors, Mouse Models of Cancer: Methods in Molecular Biology 2015, Springer.
23. Kim J.J., Shajib S., Manocha M.M., Khan W.I. Investigating intestinal inflammation in DSS-induced model of IBD. J. Vis. Exp. 2012.
24. Massagué J. TGFβ in Cancer, Cell 2008, Elsevier.
25. Meier J., ASturm Current treatment of ulcerative colitis. World J. Gastroenterol. 2011.
26. Rugtveit J., Nilsen E.M., Bakka A., Carlsen H., Brandtzaeg P., Scott H. Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 1997.
27. KD Hove, C Brøns, K Fae: rch, SS Lund, P Rossing, A Vaag Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study-Eur. J. Endocrinol., 2015.
28. Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 2000.
29. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011.
30. Feagins L.A. Role of Transforming Growth Factor-β in Inflammatory Bowel Disease and Colitis-Associated Colon Cancer-Inflammatory bowel diseases 2010, Wiley Online Library.
31. Lee, Lee S.H., Kim E.K., Kim J.K., Shin D.Y., Cho M.L. Metformin ameliorates inflammatory bowel disease by suppression of STAT3 signaling pathway and regulation of the Th17/Treg balance (THER3P. 1001). J. Immunol. 2015.
32. L Hawinkels, M Paauwe, HW Verspaget, E Wiercinska, JM van der Zon, K van der Ploeg, PJ Koelink, et al.. Interaction with colon cancer cells hyperactivates TGF-β signaling in cancer-associated fibroblasts-Oncogene, 2014.
33. Maynard C.L., Elson C.O., Hatton R.D., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489(7415):231-241.
34. Mattar M.C., Lough D., Pishvaian M.J., Charabaty A. Current management of inflammatory bowel disease and colorectal cancer. Gastrointest. Cancer Res. 2011.
35. Laukoetter M.G., Nava P., Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J. Gastroenterol. 2008.
36. Akash M.S.H., Rehman K., Chen S. Role of Inflammatory Mechanisms in Pathogenesis of Type 2 Diabetes Mellitus. Journal of Cellular Biochemistry 2013, Wiley Online Library.
37. Hayden M.S., Ghosh S. Shared Principles in NF-κB Signaling. Cell 2008, Elsevier.
38. Rubin M.R., Goldfine A.B., McMahon D.J., Donovan D.S., Cremers S., Dworakowski E., Schaefer E.J., et al. Effects of the Anti-Inflammatory Drug Salsalate on Bone Turnover in Type 2 Diabetes Mellitus-Endocrine 2015, Springer.
39. Nami Y., Abdullah N., Haghshenas B., et al. Assessment of probiotic potential and anticancer activity of newly isolated vaginal bacterium lactobacillus plantarum 5BL. Microbiol. Immunol. 2014, 58(9):492-502.
40. Erez N., Truitt M., Olson P., Hanahan D. Cancer-Associated Fibroblasts are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner, Cancer Cell 2010, Elsevier.
41. Basso P.J., Fonseca M.T.C., Bonfá G., Alves V.B.F., Sales-Campos H., Nardini V., Cardoso C.R.B. Association among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel disease. Braz. J. Med. Biol. Res. 2014.
42. Atreya R., Mudter J., Finotto S., Müllberg J., Jostock T., Wirtz S., Schütz M., et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 2010.
43. Sartor R.B. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am. J. Gastroenterol. 1997.
44. Xavier R.J., Podolsky D.K. The pathogenesis of inflammatory bowel disease. Nature 2007.
45. Duary R.K., Bhausaheb M.A., Batish V.K., Grover S. Anti-Inflammatory and Immunomodulatory Efficacy of Indigenous Probiotic Lactobacillus Plantarum Lp91 in Colitis Mouse Model. Molecular Biology Reports 2012, Springer.
46. Thoreson R., Cullen J.J. Pathophysiology of Inflammatory Bowel Disease: An Overview. Surgical Clinics of North America 2007, Elsevier.
47. Gupta S.C., Kim J.H., Prasad S., Aggarwal B.B. Regulation of Survival, Proliferation, Invasion, Angiogenesis, and Metastasis of Tumor Cells Through Modulation of Inflammatory Pathways by Nutraceuticals. Cancer Metastasis Reviews 2010, Springer.
48. SC Larsson, N Orsini, A Wolk. Diabetes mellitus and risk of colorectal cancer: a meta-analysis-J. Natl. Cancer Inst. 2005.
49. Erdman S.E., Poutahidis T. Roles for inflammation and regulatory T cells in colon cancer. Toxicol. Pathol. 2010.
50. Kahn S.E. The Relative Contributions of Insulin Resistance and Beta-Cell Dysfunction to the Pathophysiology of Type 2 Diabetes, Diabetologia 2003, Springer.
51. Fischbach S., Gittes G.K. The role of TGF-β signaling in β-cell dysfunction and type 2 diabetes: a review. J. Cytol. Histol. 2014.
52. Grivennikov S., Karin E., Terzi J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J. IL-6 and Stat3 Are Required for Survival of intestinal epithelial cells and development of Colitis-Associated Cancer Cancer cell 2009, Elsevier.
53. Hong S., Lee H.J., Kim S.J., Hahm K.B. Connection between inflammation and carcinogenesis in gastrointestinal tract: focus on TGF-β signaling. World J. Gastroenterol. 2010.
54. Vieira S.M., Lemos H.P., Grespan R., Napimoga M.H., Dal-Secco D., Freitas A., Cunha T.M., et al. A Crucial Role for TNF-α in Mediating Neutrophil Influx Induced by Endogenously Generated or Exogenous Chemokines, KC/CXCL1 and LIX/CXCL5-British journal of Pharmacology 2009, Wiley Online Library.
55. Sobhani I., Jarrousse V., Guilemeau S., et al. Colon cancer patients' microbiome induces intestinal precancerous change in germ-free mice. Gut 2011, 60(3):A1.
56. Seshasai S.R., Kaptoge S., Thompson A., Angelantonio E.D., Gao P., Sarwar N., Whincup P.H., et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011, 364:829-841.
57. Seo S.U., Chen G.Y., Núñez G., Kamada N. Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 2013.
58. Kühbacher T., Schreiber S., Fölsch U.R. Ulcerative Colitis: Conservative Management and Long-Term Effects. Langenbeck's Archives of Surgery 2004, Springer.
59. Chandrasekar V.T., Venu N. So What Is Crohn's disease and Ulcerative Colitis? Pathophysiology of Crohn's disease and Ulcerative Colitis. Inflammatory Bowel Disease 2015, Springer.
60. Strober W., Zhang F., Kitani A., Fuss I., Fichtner-Feigl S. Pro-inflammatory cytokines underlying the inflammation of Crohn's disease. Curr. Opin. Gastroenterol. 2010.
61. Feng X.H., Derynck R. Specificity and versatility in TGF-β signaling through Smads. Rev. Cell Dev. Biol. 2005.
62. Wu X., Conlin V.S., Morampudi V., Ryz N.R., Nasser Y., Bhinder G., Bergstrom K.S., et al. Vasoactive intestinal polypeptide promotes intestinal barrier homeostasis and protection against colitis in mice. PLoS One 2015.
63. Ben-Neriah Y., Karin M. Inflammation Meets Cancer, with NF-[Kappa] B as the Matchmaker-Nature Immunology 2011.
64. Liu Z., Brooks R.S., Ciappio E.D., Kim S.J., Crott J.W., Bennett G., Greenberg A.S., et al. Diet-Induced Obesity Elevates Colonic TNF-α in Mice and is Accompanied by an Activation of Wnt Signaling: A Mechanism for Obesity-Associated Colorectal Cancer-The Journal of Nutritional Biochemistry 2012, Elsevier.
65. Xu Z., Wang R., Yang Y., Dai R., Shang J., Yu Q. Intervention Effect of Probiotic Bifidobacterium on Type 2 Diabetes Mellitus Rats-Journal of Hygiene Research 2014.